Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in preterm infants. Surfactant therapy substantially reduces mortality and respiratory morbidity for this population. Secondary surfactant deficiency also contributes to acute respiratory morbidity in late-preterm and term neonates with meconium aspiration syndrome, pneumonia/sepsis, and perhaps pulmonary hemorrhage; surfactant replacement may be beneficial for these infants. This statement summarizes the evidence regarding indications, administration, formulations, and outcomes for surfactant-replacement therapy. The clinical strategy of intubation, surfactant administration, and extubation to continuous positive airway pressure and the effect of continuous positive airway pressure on outcomes and surfactant use in preterm infants are also reviewed.

Surfactant replacement was established as an effective and safe therapy for immaturity-related surfactant deficiency by the early 1990s.1 Systematic reviews of randomized, controlled trials confirmed that surfactant administration in preterm infants with established respiratory distress syndrome (RDS) reduces mortality, decreases the incidence of pulmonary air leak (pneumothoraces and pulmonary interstitial emphysema), and lowers the risk of chronic lung disease or death at 28 days of age (Table 1).2,11 Subsequent trials indicated that prophylactic or early administration of surfactant resulted in fewer pneumothoraces, less pulmonary interstitial emphysema, and improved survival without bronchopulmonary dysplasia (BPD). However, recent randomized clinical trials indicate that the benefits of prophylactic surfactant are no longer evident in groups of infants when continuous positive airway pressure (CPAP) is used routinely.5 

TABLE 1

Meta-analyses of Surfactant Replacement: Prophylaxis and Rescue Treatment With Animal-Derived and Synthetic Surfactant2,3,8,11 

OutcomeProphylactic SurfactantRescue Surfactant
Animal DerivedSyntheticAnimal DerivedSynthetic
N RR (95% CI)N RR (95% CI)N RR (95% CI)N RR (95% CI)
Neonatal mortality 8 0.60 (0.47–0.77) 7 0.70 (0.58–0.85) 10 0.68 (0.57–0.82) 6 0.73 (0.61–0.88) 
Pneumothorax 9 0.40 (0.29–0.54) 6 0.67 (0.50–0.90) 12 0.42 (0.34–0.52) 5 0.64 (0.55–0.76) 
PIE 6 0.46 (0.36–0.59) 2 0.68 (0.50–0.93) 8 0.45 (0.37–0.55) 4 0.62 (0.54–0.71) 
BPDa 8 0.91 (0.79–1.05) 4 1.06 (0.83–1.36) 12 0.95 (0.84–1.08) 5 0.75 (0.61–0.92) 
BPD/deatha 8 0.80 (0.72–0.88) 4 0.89 (0.77–1.03) 12 0.83 (0.77–0.90) 4 0.73 (0.65–0.83) 
OutcomeProphylactic SurfactantRescue Surfactant
Animal DerivedSyntheticAnimal DerivedSynthetic
N RR (95% CI)N RR (95% CI)N RR (95% CI)N RR (95% CI)
Neonatal mortality 8 0.60 (0.47–0.77) 7 0.70 (0.58–0.85) 10 0.68 (0.57–0.82) 6 0.73 (0.61–0.88) 
Pneumothorax 9 0.40 (0.29–0.54) 6 0.67 (0.50–0.90) 12 0.42 (0.34–0.52) 5 0.64 (0.55–0.76) 
PIE 6 0.46 (0.36–0.59) 2 0.68 (0.50–0.93) 8 0.45 (0.37–0.55) 4 0.62 (0.54–0.71) 
BPDa 8 0.91 (0.79–1.05) 4 1.06 (0.83–1.36) 12 0.95 (0.84–1.08) 5 0.75 (0.61–0.92) 
BPD/deatha 8 0.80 (0.72–0.88) 4 0.89 (0.77–1.03) 12 0.83 (0.77–0.90) 4 0.73 (0.65–0.83) 

N, number; PIE, pulmonary interstitial emphysema.

a

Defined at 28 d.

This clinical report updates a 2008 report from the American Academy of Pediatrics.1 As in the previous report, a number of clinically important topics are reviewed surrounding use of surfactant, including prophylactic versus rescue replacement, preparations and administration techniques, the synergistic effects of surfactant and antenatal steroids, and surfactant therapy for respiratory disorders other than RDS. In addition, the effect of CPAP on RDS and surfactant replacement and the efficacy of the INSURE approach (intubation, surfactant administration, and extubation to CPAP) are reviewed.

Surfactant trials have included infants born between 23 and 34 weeks’ gestation and/or with birth weight between 500 and 2000 g.1,12 The results of subgroup analyses from such studies indicated that surfactant therapy decreased mortality rates most effectively in infants born at less than 30 weeks’ gestation or with birth weight <1250 g.12 In addition, surfactant replacement reduced the incidence of pneumothorax, pulmonary interstitial emphysema, and the combined outcome of death or BPD, compared with no surfactant replacement12; these findings suggest that lung injury is mitigated after surfactant replacement. The incidence of other medical morbidities, such as BPD, intraventricular hemorrhage, necrotizing enterocolitis, health care–associated infections, retinopathy of prematurity, and patent ductus arteriosus, has not changed with surfactant replacement, but this may be attributable, in part, to the large reduction in mortality with surfactant replacement therapy.13 The onset of clinical signs of patent ductus arteriosus may occur earlier, and the incidence of pulmonary hemorrhage, especially in infants born at less than 27 weeks’ gestation, may be increased with surfactant therapy. Surfactant replacement is effective for larger and more mature preterm infants with established RDS.

A prophylactic, or preventive, surfactant strategy is defined as intubation and surfactant administration to infants at high risk of developing RDS for the primary purpose of preventing worsening RDS rather than treatment of established RDS; this has been operationalized in clinical studies as surfactant administration in the delivery room before initial resuscitation efforts or the onset of respiratory distress or, most commonly, after initial resuscitation but within 10 to 30 minutes after birth. This contrasts with a rescue or treatment surfactant strategy, in which surfactant is given only to preterm infants with established RDS. Rescue surfactant is most often administered within the first 12 hours after birth, when specified threshold criteria of severity of RDS are met.

The meta-analysis of studies conducted before routine application of CPAP demonstrated a lower mortality rate (relative risk [RR] 0.69; 95% confidence interval [CI] 0.56–0.85; number needed to benefit [NNTB] 20) and a decrease in the risk of air leak (RR 0.79; 95% CI 0.63–0.98) in preterm infants receiving prophylactic surfactant versus rescue surfactant.14 However, when the studies that allowed for routine application of CPAP were included in the meta-analysis (National Institute of Child Health and Human Development SUPPORT Trial and Vermont Oxford Network Delivery Room Management Trial), the benefits of prophylactic surfactant on mortality (RR 0.89; 95% CI 0.76–1.04) and air leak (RR 0.86; 95% CI 0.71–1.04) could no longer be demonstrated.5 Furthermore, infants receiving prophylactic surfactant had a higher incidence of BPD or death than did infants stabilized on CPAP (RR 1.12; 95% CI 1.02–1.24). Secondary analyses of studies that did or did not use CPAP to stabilize infants demonstrated a trend to a lower risk of intraventricular hemorrhage (RR 0.91; 95% CI 0.82–1.00) and severe intraventricular hemorrhage (RR 0.87; 95% CI 0.70–1.04) with prophylactic surfactant. That finding cannot be explained; however, there was considerable heterogeneity in the trials included in the meta-analysis. The risks of developing other complications of prematurity, such as retinopathy of prematurity, patent ductus arteriosus, and periventricular leukomalacia, were not significantly different.

When studies investigating infants born at <30 weeks’ gestation were analyzed separately,5 similar findings were noted. However, there was a trend for an increased risk of chronic lung disease in infants born at <30 weeks’ gestation who received prophylactic surfactant (RR 1.13; 95% CI 1.00–1.28) and a significant increase in death or chronic lung disease (RR 1.13; 95% CI 1.02–1.25) with use of prophylactic surfactant.

Although there are no statistically significant benefits to prophylactic use of surfactant when compared with prophylactic CPAP, several studies have investigated whether administration of surfactant early in the course of respiratory insufficiency improves clinical outcomes. Early rescue is defined as surfactant treatment within 1 to 2 hours of birth, and late rescue is defined as surfactant treatment 2 or more hours after birth. A recent meta-analysis of early (within 2 hours) versus delayed surfactant treatment concluded that the risks of mortality (RR 0.84; 95% CI 0.74–0.95), air leak (RR 0.61; 95% CI 0.48–0.78), chronic lung disease (RR 0.69; 95% CI 0.55–0.86), and chronic lung disease or death (RR 0.83; 95% CI 0.75–0.91) were significantly decreased. There were no differences in other complications of prematurity.7 

The INSURE strategy is widely used throughout the world. In randomized clinical trials performed before 2008, the INSURE approach, compared with rescue surfactant administration in infants with RDS, was associated with a significantly reduced need for mechanical ventilation (RR 0.67; 95% CI 0.57–0.79) and a reduced need for oxygen at 28 days.6 In an analysis stratified by fraction of inspired oxygen requirement at study entry, a significantly higher frequency of patent ductus arteriosus was observed among infants in the rescue surfactant group, who required a fraction of inspired oxygen greater than 0.45 (RR 2.15; 95% CI 1.09–4.23). The Vermont Oxford Network Delivery Room Management Trial (n = 648) randomly assigned infants born at 26 to 29 weeks’ gestation to 1 of 3 treatment groups: prophylactic surfactant and continued ventilation, prophylactic surfactant and rapid extubation to CPAP (INSURE), or nasal CPAP without surfactant.15 When compared with the group of infants receiving prophylactic surfactant and continued ventilation, the RR of death or BPD was 0.78 (95% CI 0.59–1.03) for the INSURE group and 0.83 (95% CI 0.64–1.09) for the CPAP group. However, in the nasal CPAP group, 48% were managed without intubation and 54% without surfactant treatment. A recent meta-analysis demonstrated that prophylactic surfactant (with rapid extubation to CPAP) was associated with a higher risk of death or BPD (RR 1.12; 95% CI 1.02–1.24; number needed to harm of 17) when compared with early stabilization with CPAP and selective surfactant administration.5 In infants with birth weight ≥1250 g and mild to moderate RDS, elective intubation and administration of surfactant decreased the need for mechanical ventilation but had no effect on the duration of oxygen therapy, ventilator therapy, or hospital stay.16 

A wide variety of animal-derived and synthetic surfactants are available commercially (Table 2); both are beneficial as therapy for RDS in preterm infants. Animal-derived surfactants are modified or purified from bovine or porcine lungs. Treatment with animal-derived surfactants (beractant [Survanta; Abbvie Inc, North Chicago, IL], calfactant [Infasurf; ONY Inc, Amherst, NY], and poractant [Curosurf; Chiesi Farmaceutici, Parma, Italy]) has several advantages over first-generation, protein-free synthetic surfactants (eg, colfosceril palmitate [Exosurf; GlaxoSmithKline, Middlesex, UK]).3 These include lower mortality rates (RR 0.86; 95% CI 0.76–0.98; number needed to harm of 40) and fewer pneumothoraces (RR 0.63; 95% CI 0.53–0.75; NNTB 22).4 Animal-derived surfactants contain variable amounts of surfactant protein B (SP-B). SP-B enhances the rate of adsorption of phospholipids at the air-water interface, is involved in the formation of tubular myelin, and has antiinflammatory properties. However, it is unclear whether significant differences in clinical outcomes exist among the available animal-derived products.

TABLE 2

Composition and Dosage of Surfactants17 

SurfactantMain PhospholipidsProteinsPhospholipid ConcentrationSuggested DosePhospholipid per Dose
Animal-derived      
 Beractant (Survantaa) minced bovine lung extract DPPC and PG (<0.1%) SP-B and (1%) SP-C 25 mg/mL 4 mL/kg 100 mg/kg 
 Calfactant (Infasurfb) bovine calf lung lavage DPPC and PG (0.7%) SP-B and (1%) SP-C 35 mg/mL 3 mL/kg 105 mg/kg 
 Poractant (Curosurfc) minced porcine lung extract DPPC and PG (0.6%)SP-B and (1%) SP-C 80 mg/mL 2.5 mL/kg and 100-200 mg/kg 
    1.25 mL/kg 100 mg/kg 
Synthetic      
 Colfosceril (ExosurfdDPPC (100%) None 13.5 mg/mL 5 mL/kg 67.5 mg/kg 
Synthetic, protein analog      
 Lucinactant (SurfaxineDPPC and POPG KL4 peptide as SP-B 30 mg/mL 5.8 mL/kg 175 mg/kg 
SurfactantMain PhospholipidsProteinsPhospholipid ConcentrationSuggested DosePhospholipid per Dose
Animal-derived      
 Beractant (Survantaa) minced bovine lung extract DPPC and PG (<0.1%) SP-B and (1%) SP-C 25 mg/mL 4 mL/kg 100 mg/kg 
 Calfactant (Infasurfb) bovine calf lung lavage DPPC and PG (0.7%) SP-B and (1%) SP-C 35 mg/mL 3 mL/kg 105 mg/kg 
 Poractant (Curosurfc) minced porcine lung extract DPPC and PG (0.6%)SP-B and (1%) SP-C 80 mg/mL 2.5 mL/kg and 100-200 mg/kg 
    1.25 mL/kg 100 mg/kg 
Synthetic      
 Colfosceril (ExosurfdDPPC (100%) None 13.5 mg/mL 5 mL/kg 67.5 mg/kg 
Synthetic, protein analog      
 Lucinactant (SurfaxineDPPC and POPG KL4 peptide as SP-B 30 mg/mL 5.8 mL/kg 175 mg/kg 

DPPC, dipalmitoyl phosphatidylcholine; PG, phosphatidylglycerol; POPG, palmitoyloleyl phosphatidylglycerol; SP-C, surfactant protein C.

a

Abbvie Inc, North Chicago, IL.

b

ONY Inc, Amherst, NY.

c

Chiesi Farmaceutici, Parma, Italy.

d

GlaxoSmithKline, Middlesex, UK.

e

Discovery Laboratories, Warrington, PA.

A synthetic surfactant (lucinactant) that contains a 21-amino acid peptide that mimics SP-B activity has recently been approved for the prevention and treatment of RDS in preterm infants.18,19 When compared with animal-derived surfactant (beractant or poractant), lucinactant was shown to be equivalent.18,19 Neonatal morbidities (intraventricular hemorrhage, periventricular leukomalacia, pulmonary hemorrhage, sepsis, patent ductus arteriosus, retinopathy of prematurity, necrotizing enterocolitis, and BPD) were not significantly different between preterm infants treated with animal-derived surfactants and those treated with synthetic surfactants.

Surfactant administration strategies have been based on manufacturer guidelines for individual surfactants.1 The dose of surfactant, frequency of administration, and treatment procedures have been modeled after research protocols. Furthermore, repeated doses of surfactants given at intervals for predetermined indications have decreased mortality and morbidity compared with placebo or single surfactant doses.10 However, given the long half-life for surfactant in preterm infants with RDS,20 redosing should not be needed more often than every 12 hours, unless surfactant is being inactivated by an infectious process, meconium, or blood. Dosing intervals shorter than 12 hours recommended by some manufacturers are not based on human pharmacokinetic data.

Surfactant administration procedures may be complicated by transient airway obstruction, oxygen desaturation, bradycardia, and alterations in cerebral blood flow and brain electrical activity. The delivery of surfactant can also result in rapid improvement in lung volume, functional residual capacity, and compliance. Thus, expeditious changes in mechanical ventilator settings may be necessary to minimize the risks of lung injury and air leak. Clinicians with expertise in these procedures should be responsible for surfactant administration whenever surfactant is given.

Surfactant has traditionally been administered through an endotracheal tube either as bolus, in smaller aliquots,21 or by infusion through an adaptor port on the proximal end of the endotracheal tube.19 In an animal model, administration of surfactant as an intratracheal bolus while disconnected from the mechanical ventilator resulted in more uniform distribution than an infusion administered over 30 minutes through a side-hole adapter.22 However, a small clinical trial of human preterm infants showed no significant differences in clinical outcomes between methods.23 During surfactant administration, reflux into the endotracheal tube occurred more often when the infusion technique was used. Similar clinical outcomes were also found when surfactant was administered as a bolus or as a 1-minute infusion through a side-hole adapter.24 Because data are conflicting and limited, the optimal method of surfactant administration in preterm infants has yet to be clearly proven. Additionally, there is insufficient evidence to recommend the optimal number of fractional doses of surfactant or what body position is best when surfactant is administered.

A number of alternatives to intratracheal administration of surfactant have been evaluated in clinical trials.25,32 These include use of aerosolized surfactant preparations, laryngeal mask airway-aided delivery of surfactant, instillation of pharyngeal surfactant, and administration of surfactant using thin intratracheal catheters. Theoretically, each of these methods could allow administration of surfactant without intubation in spontaneously breathing infants. In a recent study, Göpel et al25 randomized 220 preterm infants born at 26 to 28 weeks’ gestation to receive either surfactant administered via a thin plastic catheter (using laryngoscopy) or surfactant administered as a rescue therapy. All infants were maintained on CPAP. The administration of surfactant through a thin plastic catheter significantly reduced the need for mechanical ventilation and decreased the need for oxygen therapy at 28 days. More data are needed to recommend any of the alternative techniques for surfactant administration.

Surfactant inactivation and secondary dysfunction may occur with conditions such as meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, neonatal pneumonia, and pulmonary hemorrhage.33,34 Surfactant administration techniques, surfactant dosage, patient populations, entry criteria, and study outcomes in the small randomized trials and case series of surfactant replacement in neonates with secondary surfactant deficiency vary considerably.35,42 

Meconium aspiration syndrome with severe respiratory failure and persistent pulmonary hypertension may be complicated by surfactant inactivation. Surfactant replacement by bolus or slow infusion in infants with severe meconium aspiration syndrome improved oxygenation and reduced the need for extracorporeal membrane oxygenation (ECMO) (RR 0.64; 95% CI 0.46–0.91; NNTB 6).35 Surfactant did not reduce mortality or decrease the frequency of air leaks (pneumothoraces or pulmonary interstitial emphysema). In a blinded randomized clinical trial of infants receiving ECMO, administration of surfactant shortened the duration of the ECMO. Notably, there were no infants with congenital diaphragmatic hernia in that study.36 

Surfactant inactivation may be associated with pneumonia.37,38 In a small randomized trial of surfactant rescue therapy, the subgroup of infants with sepsis showed improved oxygenation and a reduced need for ECMO compared with a similar group of control infants.37 Newborn infants with pneumonia or sepsis receiving rescue surfactant also demonstrated improved gas exchange compared with infants without surfactant treatment. The number of neonates who received surfactant for sepsis and pneumonia in these clinical reports is small, and no recommendation can be made.

Surfactant treatment of pulmonary hemorrhage is plausible, because blood inhibits surfactant function. However, only a few retrospective and observational reports have documented the benefits of such therapy, and the magnitude of benefit remains to be established.39 

Congenital diaphragmatic hernia may be associated with surfactant insufficiency.40 Although measurements of disaturated phosphatidylcholine from lungs of infants with congenital diaphragmatic hernia show synthetic rates similar to those from infants without diaphragmatic hernia, pool sizes and kinetics are altered.40 However, surfactant treatment of a large series of infants with congenital diaphragmatic hernia did not improve outcomes. In fact, the need for ECMO, the incidence of chronic lung disease, and mortality rate were increased with surfactant administration.41,42 

Surfactant trials that proved efficacy were performed at a time when antenatal steroid therapy was given infrequently.43 By the late 1990s, most mothers of preterm infants born at less than 30 weeks’ gestation had received antenatal steroids (58% to 92%).44,46 Antenatal steroids significantly reduce mortality (RR 0.62; 95% CI 0.51–0.77; NNTB 23), RDS (RR 0.65; 95% CI 0.47–0.75; NNTB 12), and surfactant use in preterm infants (RR 0.45; 95% CI 0.22–0.93; NNTB 9),47 most consistently in those born between 28 and 34 weeks’ gestation.

Results of observational studies and clinical trials have inferred that antenatal steroids may reduce the need for prophylactic and early rescue surfactant replacement in infants born after 27 to 28 weeks’ gestation,16,48 but no randomized, controlled trials have addressed this issue. In infants born at or earlier than 27 weeks’ gestation, the incidence of RDS is not reduced after exposure to antenatal steroids; however, in a recently published study, death or neurodevelopment impairment at 18 to 22 months was significantly lower for infants who had been exposed to antenatal steroids at 23 to 25 weeks’ gestation.49 Infants born before 32 weeks’ gestation who received both antenatal steroids and postnatal surfactant were found on subgroup analyses to have significant reductions in mortality, severity of respiratory distress, and air leaks when compared with subgroups that received neither steroids nor surfactant, antenatal steroids only, or surfactant only.50,52 This finding corroborates evidence from animal models of RDS that the combination of antenatal steroids and postnatal surfactant improves lung function more than either treatment alone.53,55 

An important additional benefit of antenatal steroids is a reduction in risk of intraventricular hemorrhage, an advantage not found with surfactant replacement alone.56 The effects of antenatal steroids on other neonatal morbidities, such as necrotizing enterocolitis and patent ductus arteriosus, have been inconsistent. However, antenatal steroids have not significantly decreased the incidence of BPD.50,51 

Randomized clinical trials suggest that nasal CPAP is acceptable as an alternative to surfactant administration in preterm infants with RDS. A clinical report from the American Academy of Pediatrics, “Respiratory Support of the Preterm Infant,” is forthcoming.57 

  1. Surfactant replacement, given as prophylaxis or rescue treatment, reduces the incidence of RDS, air leaks, and mortality in preterm infants with RDS (level of evidence [LOE] 1).

  2. Both animal-derived and newer synthetic surfactants with SP-B–like activity decrease acute respiratory morbidity and mortality in preterm infants with RDS (LOE 1).

  3. Early rescue surfactant treatment (<2 hours of age) in infants with RDS decreases the risk of mortality, air leak, and chronic lung disease in preterm infants (LOE 1).

  4. Early initiation of CPAP with subsequent selective surfactant administration in extremely preterm infants results in lower rates of BPD/death when compared with treatment with prophylactic surfactant therapy (LOE 1).

  5. Surfactant replacement has not been shown to affect the incidence of neurologic, developmental, behavioral, medical, or educational outcomes in preterm infants (LOE 2).

  6. Surfactant treatment improves oxygenation and reduces the need for ECMO without an increase in morbidity in neonates with meconium aspiration syndrome (LOE 2).

  7. Surfactant treatment of infants with congenital diaphragmatic hernia does not improve clinical outcomes (LOE 2).

  8. Antenatal steroids and postnatal surfactant replacement independently and additively reduce mortality, the severity of RDS, and air leaks in preterm infants (LOE 2).

TABLE 3

Levels of Evidence59

Recommendation LOELOEGrade of Recommendation
Preterm infants born at <30 wk of gestation who need mechanical ventilation because of severe RDS should be given surfactant after initial stabilization. Strong Recommendation 
Using CPAP immediately after birth with subsequent selective surfactant administration should be considered as an alternative to routine intubation with prophylactic or early surfactant administration in preterm infants. Strong Recommendation 
Rescue surfactant may be considered for infants with hypoxic respiratory failure attributable to secondary surfactant deficiency (eg, meconium aspiration syndrome or sepsis/pneumonia). Recommendation 
Recommendation LOELOEGrade of Recommendation
Preterm infants born at <30 wk of gestation who need mechanical ventilation because of severe RDS should be given surfactant after initial stabilization. Strong Recommendation 
Using CPAP immediately after birth with subsequent selective surfactant administration should be considered as an alternative to routine intubation with prophylactic or early surfactant administration in preterm infants. Strong Recommendation 
Rescue surfactant may be considered for infants with hypoxic respiratory failure attributable to secondary surfactant deficiency (eg, meconium aspiration syndrome or sepsis/pneumonia). Recommendation 
  1. Preterm infants born at <30 weeks’ gestation who need mechanical ventilation because of severe RDS should be given surfactant after initial stabilization (Strong Recommendation).

  2. Using CPAP immediately after birth with subsequent selective surfactant administration should be considered as an alternative to routine intubation with prophylactic or early surfactant administration in preterm infants (Strong Recommendation).

  3. Rescue surfactant may be considered for infants with hypoxic respiratory failure attributable to secondary surfactant deficiency (eg, pulmonary hemorrhage, meconium aspiration syndrome, or sepsis/pneumonia) (Recommendation).

  4. Preterm and term neonates who are receiving surfactant should be managed by nursery and transport personnel with the technical and clinical expertise to administer surfactant safely and deal with multisystem illness. Therefore, pediatric providers who are without expertise, or who are inexperienced or uncomfortable with surfactant administration or managing an infant who has received surfactant should wait for the transport team to arrive.

Richard A. Polin, MD, FAAP

Waldemar A. Carlo, MD, FAAP

Lu-Ann Papile, MD, FAAP, Chairperson

Richard A. Polin, MD, FAAP

Waldemar A. Carlo, MD, FAAP

Rosemarie Tan, MD, FAAP

Praveen Kumar, MD, FAAP

William Benitz, MD, FAAP

Eric Eichenwald, MD, FAAP

James Cummings, MD, FAAP

Jill Baley, MD, FAAP

Roger F. Soll, MD, FAAP

Tonse N. K. Raju, MD, FAAP – National Institutes of Health

CAPT Wanda Denise Barfield, MD, FAAP – Centers for Disease Control and Prevention

Erin Keels, MSN – National Association of Neonatal Nurses

Anne Jefferies, MD – Canadian Pediatric Society

Kasper S. Wang, MD, FAAP – AAP Section on Surgery

George Macones, MD – American College of Obstetricians and Gynecologists

Jim Couto, MA

Dr Carlo is on the Mednax Board of Directors.

Dr Polin is a consultant for Discovery Laboratories.

     
  • BPD

    bronchopulmonary dysplasia

  •  
  • CI

    confidence interval

  •  
  • CPAP

    continuous positive airway pressure

  •  
  • ECMO

    extracorporeal membrane oxygenation

  •  
  • INSURE

    intubation, surfactant administration, and extubation

  •  
  • LOE

    level of evidence

  •  
  • NNTB

    number needed to benefit

  •  
  • RDS

    respiratory distress syndrome

  •  
  • RR

    relative risk

  •  
  • SP-B

    surfactant protein B

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

1
Engle
WA
American Academy of Pediatrics Committee on Fetus and Newborn
.
Surfactant-replacement therapy for respiratory distress in the preterm and term neonate.
Pediatrics
.
2008
;
121
(
2
):
419
432
[PubMed]
2
Soll
RF
.
Synthetic surfactant for respiratory distress syndrome in preterm infants.
Cochrane Database Syst Rev
.
2000
;(
2
):
CD001149
[PubMed]
3
Seger
N
,
Soll
R
.
Animal derived surfactant extract for treatment of respiratory distress syndrome.
Cochrane Database Syst Rev
.
2009
; (
2
):
CD007836
[PubMed]
4
Soll
RF
,
Blanco
F
.
Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome.
Cochrane Database Syst Rev
.
2001
;(
2
):
CD000144
[PubMed]
5
Rojas-Reyes
MX
,
Morley
CJ
,
Soll
R
.
Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.
Cochrane Database Syst Rev
.
2012
;
3
(
3
):
CD000510
[PubMed]
6
Stevens
TP
,
Harrington
EW
,
Blennow
M
,
Soll
RF
.
Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.
Cochrane Database Syst Rev
.
2007
;(
4
):
CD003063
[PubMed]
7
Bahadue
FL
,
Soll
R
.
Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.
Cochrane Database Syst Rev
.
2012
;
11
(
11
):
CD001456
[PubMed]
8
Soll
R
,
Ozek
E
.
Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants.
Cochrane Database Syst Rev
.
2010
;(
1
):
CD001079
[PubMed]
9
Pfister
RH
,
Soll
R
,
Wiswell
TE
.
Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
Cochrane Database Syst Rev
.
2009
;(
4
):
CD006180
[PubMed]
10
Soll
R
,
Ozek
E
.
Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome.
Cochrane Database Syst Rev
.
2009
;(
1
):
CD000141
[PubMed]
11
Soll
RF
.
Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants.
Cochrane Database Syst Rev
.
2000
;(
2
):
CD000511
[PubMed]
12
Suresh
GK
,
Soll
RF
.
Overview of surfactant replacement trials.
J Perinatol
.
2005
;
25
(
suppl 2
):
S40
S44
[PubMed]
13
Philip
AG
.
Neonatal mortality rate: is further improvement possible?
J Pediatr
.
1995
;
126
(
3
):
427
433
[PubMed]
14
Soll
RF
,
Morley
CJ
.
Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.
Cochrane Database Syst Rev
.
2001
;(
2
):
CD000510
[PubMed]
15
Dunn
MS
,
Kaempf
J
,
de Klerk
A
, et al
Vermont Oxford Network DRM Study Group
.
Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates.
Pediatrics
.
2011
;
128
(
5
). Available at: www.pediatrics.org/cgi/content/full/128/5/e1069
[PubMed]
16
Escobedo
MB
,
Gunkel
JH
,
Kennedy
KA
, et al
Texas Neonatal Research Group
.
Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial.
J Pediatr
.
2004
;
144
(
6
):
804
808
[PubMed]
17
Moya
F
,
Javier
MC
.
Myth: all surfactants are alike.
Semin Fetal Neonatal Med
.
2011
;
16
(
5
):
269
274
[PubMed]
18
Sinha
SK
,
Lacaze-Masmonteil
T
,
Valls i Soler
A
, et al
Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group
.
A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Pediatrics
.
2005
;
115
(
4
):
1030
1038
[PubMed]
19
Moya
F
,
Sinha
S
,
Gadzinowski
J
, et al
SELECT and STAR Study Investigators
.
One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.
Pediatrics
.
2007
;
119
(
6
). Available at: www.pediatrics.org/cgi/content/full/119/6/e1361
[PubMed]
20
Cogo
PE
,
Facco
M
,
Simonato
M
, et al
.
Pharmacokinetics and clinical predictors of surfactant redosing in respiratory distress syndrome.
Intensive Care Med
.
2011
;
37
(
3
):
510
517
[PubMed]
21
Kendig
JW
,
Ryan
RM
,
Sinkin
RA
, et al
.
Comparison of two strategies for surfactant prophylaxis in very premature infants: a multicenter randomized trial.
Pediatrics
.
1998
;
101
(
6
):
1006
1012
[PubMed]
22
Ueda
T
,
Ikegami
M
,
Rider
ED
,
Jobe
AH
.
Distribution of surfactant and ventilation in surfactant-treated preterm lambs.
J Appl Physiol (1985)
.
1994
;
76
(
1
):
45
55
[PubMed]
23
Zola
EM
,
Gunkel
JH
,
Chan
RK
, et al
.
Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome.
J Pediatr
.
1993
;
122
(
3
):
453
459
[PubMed]
24
Valls-i-Soler
A
,
López-Heredia
J
,
Fernández-Ruanova
MB
,
Gastiasoro
E
Spanish Surfactant Collaborative Group
.
A simplified surfactant dosing procedure in respiratory distress syndrome: the “side-hole” randomized study.
Acta Paediatr
.
1997
;
86
(
7
):
747
751
[PubMed]
25
Göpel
W
,
Kribs
A
,
Ziegler
A
, et al
German Neonatal Network
.
Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial.
Lancet
.
2011
;
378
(
9803
):
1627
1634
[PubMed]
26
Schmölzer
GM
,
Agarwal
M
,
Kamlin
CO
,
Davis
PG
.
Supraglottic airway devices during neonatal resuscitation: an historical perspective, systematic review and meta-analysis of available clinical trials.
Resuscitation
.
2013
;
84
(
6
):
722
730
[PubMed]
27
Kribs
A
.
How best to administer surfactant to VLBW infants?
Arch Dis Child Fetal Neonatal Ed
.
2011
;
96
(
4
):
F238
F240
[PubMed]
28
Mehler
K
,
Grimme
J
,
Abele
J
,
Huenseler
C
,
Roth
B
,
Kribs
A
.
Outcome of extremely low gestational age newborns after introduction of a revised protocol to assist preterm infants in their transition to extrauterine life.
Acta Paediatr
.
2012
;
101
(
12
):
1232
1239
[PubMed]
29
Abdel-Latif
ME
,
Osborn
DA
.
Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.
Cochrane Database Syst Rev
.
2011
;(
7
):
CD008309
[PubMed]
30
Abdel-Latif
ME
,
Osborn
DA
.
Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome.
Cochrane Database Syst Rev
.
2012
;(
10
):
CD008310
[PubMed]
31
Abdel-Latif
ME
,
Osborn
DA
.
Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome.
Cochrane Database Syst Rev
.
2011
;(
3
):
CD008311
[PubMed]
32
Abdel-Latif
ME
,
Osborn
DA
,
Challis
D
.
Intra-amniotic surfactant for women at risk of preterm birth for preventing respiratory distress in newborns.
Cochrane Database Syst Rev
.
2010
;(
1
):
CD007916
[PubMed]
33
Finer
NN
.
Surfactant use for neonatal lung injury: beyond respiratory distress syndrome.
Paediatr Respir Rev
.
2004
;
5
(
suppl A
):
S289
S297
[PubMed]
34
Donn
SM
,
Dalton
J
.
Surfactant replacement therapy in the neonate: beyond respiratory distress syndrome.
Respir Care
.
2009
;
54
(
9
):
1203
1208
[PubMed]
35
El Shahed
AI
,
Dargaville
P
,
Ohlsson
A
,
Soll
RF
.
Surfactant for meconium aspiration syndrome in full term/near term infants.
Cochrane Database Syst Rev
.
2007
;(
3
):
CD002054
[PubMed]
36
Lotze
A
,
Knight
GR
,
Martin
GR
, et al
.
Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation.
J Pediatr
.
1993
;
122
(
2
):
261
268
[PubMed]
37
Tan
K
,
Lai
NM
,
Sharma
A
.
Surfactant for bacterial pneumonia in late preterm and term infants.
Cochrane Database Syst Rev
.
2012
;(
2
):
CD008155
[PubMed]
38
Vento
GM
,
Tana
M
,
Tirone
C
, et al
.
Effectiveness of treatment with surfactant in premature infants with respiratory failure and pulmonary infection.
Acta Biomed
.
2012
;
83
(
suppl 1
):
33
36
[PubMed]
39
Aziz
A
,
Ohlsson
A
.
Surfactant for pulmonary haemorrhage in neonates.
Cochrane Database Syst Rev
.
2012
;(
7
):
CD005254
[PubMed]
40
Cogo
PE
,
Zimmermann
LJ
,
Meneghini
L
, et al
.
Pulmonary surfactant disaturated-phosphatidylcholine (DSPC) turnover and pool size in newborn infants with congenital diaphragmatic hernia (CDH).
Pediatr Res
.
2003
;
54
(
5
):
653
658
[PubMed]
41
Van Meurs
K
Congenital Diaphragmatic Hernia Study Group
.
Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia?
J Pediatr
.
2004
;
145
(
3
):
312
316
[PubMed]
42
Lally
KP
,
Lally
PA
,
Langham
MR
, et al
Congenital Diaphragmatic Hernia Study Group
.
Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia.
J Pediatr Surg
.
2004
;
39
(
6
):
829
833
[PubMed]
43
Wright
LL
,
Horbar
JD
,
Gunkel
H
, et al
.
Evidence from multicenter networks on the current use and effectiveness of antenatal corticosteroids in low birth weight infants.
Am J Obstet Gynecol
.
1995
;
173
(
1
):
263
269
[PubMed]
44
Chien
LY
,
Ohlsson
A
,
Seshia
MM
,
Boulton
J
,
Sankaran
K
,
Lee
SK
Canadian Neonatal Network
.
Variations in antenatal corticosteroid therapy: a persistent problem despite 30 years of evidence.
Obstet Gynecol
.
2002
;
99
(
3
):
401
408
[PubMed]
45
Horbar
JD
,
Badger
GJ
,
Carpenter
JH
, et al
Members of the Vermont Oxford Network
.
Trends in mortality and morbidity for very low birth weight infants, 1991-1999.
Pediatrics
.
2002
;
110
(
1 pt 1
):
143
151
[PubMed]
46
St John
EB
,
Carlo
WA
.
Respiratory distress syndrome in VLBW infants: changes in management and outcomes observed by the NICHD Neonatal Research Network.
Semin Perinatol
.
2003
;
27
(
4
):
288
292
[PubMed]
47
Roberts
D
,
Dalziel
S
.
Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.
Cochrane Database Syst Rev
.
2006
;(
3
):
CD004454
[PubMed]
48
Gortner
L
,
Wauer
RR
,
Hammer
H
, et al
.
Early versus late surfactant treatment in preterm infants of 27 to 32 weeks’ gestational age: a multicenter controlled clinical trial.
Pediatrics
.
1998
;
102
(
5
):
1153
1160
[PubMed]
49
Carlo
WA
,
McDonald
SA
,
Fanaroff
AA
, et al
Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
.
Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks’ gestation.
JAMA
.
2011
;
306
(
21
):
2348
2358
[PubMed]
50
Jobe
AH
,
Mitchell
BR
,
Gunkel
JH
.
Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants.
Am J Obstet Gynecol
.
1993
;
168
(
2
):
508
513
[PubMed]
51
Kari
MA
,
Hallman
M
,
Eronen
M
, et al
.
Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study.
Pediatrics
.
1994
;
93
(
5
):
730
736
[PubMed]
52
White
A
,
Marcucci
G
,
Andrews
E
,
Edwards
K
,
Long
W
The American Exosurf Neonatal Study Group I and The Canadian Exosurf Neonatal Study Group
.
Antenatal steroids and neonatal outcomes in controlled clinical trials of surfactant replacement.
Am J Obstet Gynecol
.
1995
;
173
(
1
):
286
290
[PubMed]
53
Seidner
S
,
Pettenazzo
A
,
Ikegami
M
,
Jobe
A
.
Corticosteroid potentiation of surfactant dose response in preterm rabbits.
J Appl Physiol (1985)
.
1988
;
64
(
6
):
2366
2371
[PubMed]
54
Ikegami
M
,
Jobe
AH
,
Seidner
S
,
Yamada
T
.
Gestational effects of corticosteroids and surfactant in ventilated rabbits.
Pediatr Res
.
1989
;
25
(
1
):
32
37
[PubMed]
55
Gladstone
IM
,
Mercurio
MR
,
Devenny
SG
,
Jacobs
HC
.
Antenatal steroids, postnatal surfactant, and pulmonary function in premature rabbits.
J Appl Physiol (1985)
.
1989
;
67
(
4
):
1377
1382
[PubMed]
56
National Institutes of Health
.
Effect of corticosteroids for fetal maturation on perinatal outcomes.
NIH Consens Statement
.
1994
;
12
(
2
):
1
24
[PubMed]
57
Carlo
W
,
Polin
RA
American Academy of Pediatrics, Committee on Fetus and Newborn
.
Respiratory support in preterm infants at birth.
Pediatrics
. I
n press
58
US Preventive Services Task Force. Grade definition recommendations after 2007. Available at: www.uspreventiveservicestaskforce.org/uspstf/grades.htm. Accessed June 7, 2013